Publications by Antoine Regnault

Peer-reviewed publications

  1. Rofail D, Regnault A, le Scouiller S, Lambert J, Zarit SH. Assessing the impact on caregivers of patients with schizophrenia: psychometric validation of the Schizophrenia Caregiver Questionnaire (SCQ). BMC psychiatry. 2016;16:245.
  2. Rofail D, Regnault A, le Scouiller S, Berardo CG, Umbricht D, Fitzpatrick R. Health-related quality of life in patients with prominent negative symptoms: results from a multicenter randomized Phase II trial on bitopertin. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2016;25(1):201-11.
  3. Robinson DJ, Esseltine DL, Regnault A, Meunier J, Liu K, van De Velde H. The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials. British journal of haematology. 2016;174(3):368-81.
  4. Chowdary P, Kearney S, Regnault A, Hoxer CS, Yee DL. Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product. Haemophilia. 2016;22(4):e267-74.
  5. Seremetis S, Kulkarni R, Regnault A, Santagostino E. Turoctocog alfa in the treatment of individuals with hemophilia A: review of quality of life data collected in Phase III trials. Clinical Investigation. 2015;5(9):755-66.
  6. Rofail D, Acquadro C, Izquierdo C, Regnault A, Zarit SH. Cross-cultural adaptation of the Schizophrenia Caregiver Questionnaire (SCQ) and the Caregiver Global Impression (CaGI) Scales in 11 languages. Health and quality of life outcomes. 2015;13:76.
  7. Regnault A, Herdman M. Using quantitative methods within the Universalist model framework to explore the cross-cultural equivalence of patient-reported outcome instruments. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2015;24(1):115-24.
  8. Regnault A, Hamel JF, Patrick DL. Pooling of cross-cultural PRO data in multinational clinical trials: how much can poor measurement affect statistical power? Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2015;24(2):273-7.
  9. Regnault A, Burlina A, Cunningham A, Bettiol E, Moreau-Stucker F, Benmedjahed K, et al. Development and psychometric validation of measures to assess the impact of phenylketonuria and its dietary treatment on patients’ and parents’ quality of life: the phenylketonuria – quality of life (PKU-QOL) questionnaires. Orphanet journal of rare diseases. 2015;10:59.
  10. Ozelo M, Chowdary P, Regnault A, Busk AK. Impact of severe haemophilia A on patients’ health status: results from the guardian() 1 clinical trial of turoctocog alfa (NovoEight((R)) ). Haemophilia. 2015;21(4):451-7.
  11. Bosch AM, Burlina A, Cunningham A, Bettiol E, Moreau-Stucker F, Koledova E, Benmedjahed K, Regnault A. Assessment of the impact of phenylketonuria and its treatment on quality of life of patients and parents from seven European countries. Orphanet journal of rare diseases. 2015;10:80.
  12. Acquadro C, Regnault A. Patient-reported outcomes in drug development for hematology. Hematology American Society of Hematology Education Program. 2015;2015:496-500.
  13. Santagostino E, Lentz SR, Busk AK, Regnault A, Iorio A. Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa. Haemophilia. 2014;20(4):527-34.
  14. Baron R, Backonja MM, Eldridge P, Levy R, Vissers K, Attal N, Buchser E, Cruccu G, De Andres J, Hansson P, Jacobs M, Loeser JD, Prager JP, Stanton Hicks M, Regnault A, Van den Abeele C, Taylor RS. Refractory Chronic Pain Screening Tool (RCPST): a feasibility study to assess practicality and validity of identifying potential neurostimulation candidates. Pain Med. 2014;15(2):281-91.
  15. Anthoine E, Moret L, Regnault A, Sebille V, Hardouin JB. Sample size used to validate a scale: a review of publications on newly-developed patient reported outcomes measures. Health and quality of life outcomes. 2014;12:176.
  16. van Seventer R, Vos C, Giezeman M, Meerding WJ, Arnould B, Regnault A, et al. Validation of the Dutch version of the DN4 diagnostic questionnaire for neuropathic pain. Pain Pract. 2013;13(5):390-8.
  17. Lapillonne A, Regnault A, Gournay V, Gouyon JB, Benmedjahed K, Anghelescu D, et al. Development of a questionnaire to assess the impact on parents of their infant’s bronchiolitis hospitalization. BMC Health Serv Res. 2013;13(1):272.
  18. Regnault A, Balp MM, Kulich K, Viala-Danten M. Validation of the Treatment Satisfaction Questionnaire for Medication in patients with cystic fibrosis. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 2012;11(6):494-501.
  19. Lapillonne A, Regnault A, Gournay V, Gouyon JB, Gilet H, Anghelescu D, et al. Impact on parents of bronchiolitis hospitalization of full-term, preterm and congenital heart disease infants. BMC Pediatr. 2012;12:171.
  20. Delforge M, Dhawan R, Robinson D, Jr., Meunier J, Regnault A, Esseltine DL, et al. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial. Eur J Haematol. 2012;89(1):16-27.
  21. Breuil V, Cortet B, Cotte FE, Arnould B, Dias-Barbosa C, Gaudin AF, Regnault A, et al. Validation of the adherence evaluation of osteoporosis treatment (ADEOS) questionnaire for osteoporotic post-menopausal women. Osteoporos Int. 2012;23(2):445-55.
  22. Rofail D, Taylor F, Regnault A, Filonenko A. Treatment satisfaction instruments for different purposes during a product’s lifecycle: keeping the end in mind. Patient. 2011;4(4):227-40.
  23. Aguilaniu B, Gonzalez-Bermejo J, Regnault A, Dias-Barbosa C, Arnould B, Mueser M, et al. Disability related to COPD tool (DIRECT): towards an assessment of COPD-related disability in routine practice. Int J Chron Obstruct Pulmon Dis. 2011;6:387-98.
  24. Regnault A, Viala-Danten M, Gilet H, Berdeaux G. Scoring and psychometric properties of the Eye-Drop Satisfaction Questionnaire (EDSQ), an instrument to assess satisfaction and compliance with glaucoma treatment. BMC Ophthalmol. 2010;10:1.
  25. Nordmann JP, Baudouin C, Renard JP, Denis P, Regnault A, Berdeaux G. Identification of noncompliant glaucoma patients using Bayesian networks and the Eye-Drop Satisfaction Questionnaire. Clin Ophthalmol. 2010;4:1489-96.
  26. Bredart A, Sultan S, Regnault A. Patient satisfaction instruments for cancer clinical research or practice. Expert Rev Pharmacoecon Outcomes Res. 2010;10(2):129-41.
  27. Regnault A, Marfatia S, Louie M, Mear I, Meunier J, Viala-Danten M. Satisfactory cross-cultural validity of the ACTG symptom distress module in HIV-1-infected antiretroviral-naive patients. Clin Trials. 2009;6(6):574-84.
  28. Regnault A, de la Loge C, Bounekkar A, Lamure M. Le fonctionnement différentiel de l’item dans la démarche d’évaluation de la validité transculturelle des questionnaires patients. Sante et Systemique. 2006;9(1-2):175-203.
  29. Regnault A, Vigneux M,Trudeau E. La mesure de la satisfaction comme indicateur de la qualité de la prise en charge lors du retour et/ou du maintien au domicile: disposons-nous des bons instruments ? Sante et Systemique. 2005;8:197-212.
  30. Barberger-Gateau P, Alioum A, Peres K, Regnault A, Fabrigoule C, Nikulin M, et al. The contribution of dementia to the disablement process and modifying factors. Dement Geriatr Cogn Disord. 2004;18(3-4):330-7.

 

Oral communications

  1. Symonds T, Wyrwich KW, Regnault A, Coons SJ. Moving the Science Forward: Tackling Key Psychometric and Methodological Issues Facing the Field of Clinical Outcome Assessment. ISPOR; 2015; Milan, Italy.
  2. Regnault A, Rofail D, Benmedjahed K, Acquadro C, Anfray C. Caring about Caregivers: Definitions, Methods and Importance of Evaluating Caregiver Burden. ISOQOL; 2015; Vancouver, Canada.
  3. Moderator: Regnault A, Speakers: Symonds T, Houyez F, Arnould B. Can Mixed Methods Research be the Solution to the Challenges of Patient-Centered Outcome Research in the Context of Rare Diseases? ISPOR; 2014; Amsterdam, The Netherlands.
  4. Fofana F, Bonnaud-Antignac A, Regnault A. A mixed method approach to help demonstrate saturation in qualitative research: applying Partial Least Square regression to qualitative data. 1st Mixed Methods International Research Association (MMIRA) Annual Conference; 2014; Boston, USA.
  5. Moderator: Regnault A, Speakers: Patrick D, Carrita P, Pavlovic M. Demonstrating treatment benefit using clinical outcomes assessments in global clinical trials: how reliable are the assessments from cross-cultural settings? ISPOR; 2013; Dublin, Ireland.
  6. Regnault A, Brown C, Bergman G. Adherence as a differentiating factor in the appraisal of new treatments: Should economic evaluation consider whether patients take their treatment appropriately? ISPOR; 2012; Berlin, Germany.
  7. Regnault A, Arnould B, Anfray C. Assessing Health Outcomes in a Global Clinical Research Setting: Challenges and Solutions to Manage Cultural Variability. ISOQOL; 2012; Budapest, Hungary.
  8. Regnault A, Gilet H, Meunier J, Arnould B. Statistical approach to development and validation of patient-reported outcomes tools for individual decision-making. International symposium on Patient-Reported Outcome and Quality of Life; 2011; Paris, France.
  9. Regnault A, Balp MM, Kulich K, Estève L, Viala-Danten M. Validation of the treatment satisfaction questionnaire for medication (TSQM) in cystic fibrosis (CF). 34th European Cystic Fibrosis Conference; 2011; Hamburg, Germany.
  10. Regnault A, Arnould B, Anfray C. Managing Cultural Variability in PRO Measurement in a Global Clinical Research Setting. ISOQOL; 2011; Denver, USA.
  11. Gonzalez-Bermejo J, Aguilaniu B, Mueser M, Regnault A, Similowski T. Etude ADL- Typologie des patients. 15e congrès de Pneumologie de Langue Française; 2011; Lille, France.
  12. Regnault A, Siliman G, Dubois D, Kerstens R, Marant C. Development of symptom measures reflecting the relative impact of symptoms on Health-Related Quality of Life: Application to chronic constipation. ISOQOL; 2010; London, UK.
  13. Regnault A, Gilet H, Meerding WJ, Arnould B. Methodological challenges for the evaluation of patient-reported screening tools: Example of a neuropathic pain screening tool. 31st Annual conference of the International Society for Clinical Biostatistics (ISCB); 2010; Montpellier, France.
  14. Regnault A, Arnould B, Cortet B, Legrand E, Breuil V, Gaudin AF, et al. Prediction of treatment discontinuation of osteoporotic patients using ADEOS score. European League against Rheumatism (EULAR) congress; 2010; Rome, Italy.
  15. Mear I, Conway K, Regnault A, Acquadro C. Similarities and Differences in the Expression of Symptoms Across Countries: The Translations of the PAGI-SYM 20. ISOQOL; 2010; London, UK.
  16. Gonzalez-Bermejo J, Aguilaniu B, Mueser M, Regnault A, Arnould B, Dias-Barbosa C, et al. Etude ADL. Validation du questionnaire BPCO et Activités quotidiennes, un questionnaire court d’évaluation du handicap des patients BPCO. 14ème congrès de Pneumologie de Langue Française; 2010; Marseille, France.
  17. Rofail D, Regnault A, Baladi JF, Berdeaux G. Assessing treatment satisfaction during a product’s lifecyle to facilitate market access: Definitions, framework, and measurement. ISPOR; 2009; Paris, France.
  18. Regnault A, Carita P, Gilet H, Arnould B. Modélisation par équations structurelles de la satisfaction des patients vis-à-vis de leur traitement anticoagulant. Modèles et Apprentissage en Sciences Humaines et Sociales; 2009; Toulouse, France.
  19. Legrand E, Breuil V, Cortet B, Roborel de Climens A, Dias-Barbosa C, Regnault A, et al. Développement et validation du questionnaire «Adhésion et Ostéoporose» (ADEOS), un instrument d’évaluation de l’adhésion des patientes au traitement de l’ostéoporose utilisable en pratique médicale courante. 22e congrès de la Société Française de Rhumatologie; 2009; Paris, France.
  20. Regnault A, Mear I, Marfatia S, Mollon P. Addressing cross-cultural issues with Patient-Reported Outcomes assessments to strengthen evidence obtained in an international context. ISPOR; 2008; Athens, Greece.
  21. Regnault A, de la Loge C, Bounekkar A, Lamure M. Detection of Differential Item Functioning with Ordinal Response Format: Application of Ordinal Log-Linear Models. 5th Conference of the International Test Commission; 2006; Brussels, Belgium.
  22. Regnault A, de la Loge C, Arnould B, Lamure M. Quantitative aspects of an Operational Procedure to Assess Cross-Cultural Equivalence: Description and Applications. ISOQOL; 2006; Lisboa, Portugal.
  23. Arnould B, Regnault A, Girod I, Dubois D. Psychometric Tools designed for Medical Decision Making: Methodological and Analytical issues in item reduction, scoring, decision rule definition, and assessment of predictive validity. European Society for Medical Decision Making 9th Biennial Conference; 2004; Rotterdam, The Netherlands.
  24. Arnould B, de la Loge C, Abetz L, Regnault A, Duru G. Screeners, symptom and disability scales for use in clinical practice: their contribution to improve the use of drugs. ISPOR; 2004; Hamburg, Germany.
  25. Alioum A, Peres K, Verret C, Regnault A, Barberger-Gateau P. Determinants of progression and recovery through states of disability: use of a Markov model with piecewise constant intensities and covariates. Longevity, aging and degradation models; 2004; St Petersburg.

 

Posters

  1. Regnault A, Denoncourt RN, Strahs A, Agarwal S, Marquis P, Cano S. Measurement properties of the Rasch-built overall disability scale in patients with hereditary ATTR Amyloidosis with polyneuropathy.  ISPOR; Boston, MA, USA, 2017.
  2. Le Scouiller S, Edgar C, Rylands A, Giroudet C, Regnault A, Zarit S, et al. Cross-cultural adaptation of the Zarit Caregiver Interview for Alzheimer’s disease (ZCI-AD) and the Caregiver Global Impression Scales in 13 languages.  ISPOR; Vienna, Austria, 2016.
  3. Regnault A, Ferrer L, Dinet J, Gabriel S, Pavel ME, Ruszniewski PB, et al. Health-Related Quality of Life in CLARINET, a phase III Trial of Lanreotide Autogel 120mg in Patients with Non-Functioning Entero-Pancreatic neuroendocrine Tumour: Analytical Challenges and Statistical Solutions. ISOQOL; Vancouver, Canada, 2015.
  4. Acquadro C, Perret C, Regnault A. Pro Claims in Fibromyalgia: A Review of the Labels of Products Approved by the FDA and the EMA. ISPOR; Milan, Italy, 2015.
  5. Rofail D, Regnault A, le Scoullier S, Galani Berardo C, Umbricht D, Fitzpatrick R. Health-related quality of life in people with prominent negative symptoms: results form a multi-center randomised phase II trial on bitopertin. American Psychiatric Association 167th Annual Meeting; New York, NY, USA, 2014.
  6. Ozelo M, Chowdary P, Regnault A, Busk AK. Impact of severe haemophilia A on patients’ health status: results from the guardian™ 1 clinical trial of turoctocog alfa. World Federation of Hemophilia Congress; Melbourne, Australia, 2014.
  7. Bosch AM, Burlina A, Cunningham A, Bettiol EO, Moreau-Stucker F, Benmedjahed K, Regnault A. Psychometric Validation of the Newly Developed Phenylketonuria- Quality of Life (Pku-Qol) Questionnaires Assessing the Impact of Phenylketonuria and Its Treatment On Patients’ Quality of Life. ISPOR; Amsterdam, The Netherlands, 2014.
  8. Bosch A, Burlina A, Cunningham A, Bettiol E, Moreau-Stucker F, Benmedjahed K, Regnault A. Development and validation of disease-specific quality of life questionnaires for individuals with phenylketonuria and their parents. Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium; Innsbruck, Austria, 2014.
  9. Strand V, Merrill J, Nikai E, Kilgallen B, Regnault A, Gordon C. Sustained Improvements in Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus Following Epratuzumab Treatment: Results from a Phase IIb Study and its Open-Label Extension.  ISPOR; Montreal, Canada, 2014.
  10. Bosch A, Burlina A, Cunningham A, Bettiol E, Moreau-Stucker F, Benmedjahed K, Regnaut A. Psychometric validation of questionnaires assessing the impact of phenylketonuria on patients and caregivers’ quality of life. ISPOR; Amsterdam, The Netherlands, 2014.
  11. Acquadro C, Regnault A, Arnould B. Regulatory Issues in Pro Advertising: A Review of the Ddmac/Opdp Letters From 1998 To 2013 To Identify Pro Claims Violations and Examine Their Evolution Over Time. ISPOR; Amsterdam, The Netherlands, 2014.
  12. Strand V, Merrill J, Nikai E, Kilgallen B, Regnault A, Gordon C. Sustained Improvements in Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus Following Epratuzumab Treatment: Results from a Phase IIb Study and its Open-Label Extension. European Lupus Meeting; Athens, Greece, 2014.
  13. Strand V, Merrill J, Nikai E, Kilgallen B, Regnault A, Gordon C. Sustained Improvements in Health-related Quality of Life in Patients with Systemic Lupus Erythematosus (SLE) following Epratuzumab treament: Results from EMBLEM™ and its Open-Label Extension Study. American College of Rheumatology (ACR); San Diego, USA, 2013.
  14. Socinski MA, Butts CA, Mitchell P, Thatcher N, Scagliotti G, Robinet G, Martin C, Zukin M, Ragulin YA, Bonomi P, Yang JCH, Regnault A, et al. Exploration of patient health status as measured by the EQ-5D questionnaire alongside the START trial of tecemotide (L-BLP25) in NSCLC. World Conference on Lung Cancer; Sydney, Australia, 2013.
  15. Santagostino E, Lentz S, Iorio A, Busk AK, Abad Franch L, Meunier J, Regnault A. Effect of turoctocog alfa on quality of life of children, adolescents and adults with haemophilia A: Results from two clinical trials. 6th Annual Congress of the European Association for Haemophilia and Allied Disorders; Warsaw, Poland, 2013.
  16. Fofana F, Bonnaud-Antignac A, Guillemin I, Marrel A, Beriot-Mathiot A, Regnault A. Applying partial least square regression to further explore concept structure and interviewee profiles in qualitative research. ISOQOL 20th Annual Conference; Miami, FL, USA, 2013.
  17. Fofana F, Bonnaud-Antignac A, Guillemin I, Marrel A, Beriot-Mathiot A, Regnault A. A mixed method approach to saturation: applying partial least square regression to qualitative data. ISOQOL 20th Annual Conference; Miami, FL, USA, 2013.
  18. Arnould B, Gauchoux R, Meunier J, Gilet H, Regnault A. Validation of ACCEPT, a new generic measure to assess how patients with chronic diseases balance between the advantages and disadvantages of following the recommended treatment regimen in real-life. ISPOR; Dublin, Ireland, 2013.
  19. Gilet H, Regnault A. Analysis of time to patient-reported outcome meaningful change: illustration from a clinical trial of catumaxomab in patients with malignant ascites. International Society for Clinical Biostatistics (ISCB) 33rd Annual Conference; Bergen, Norway, 2012.
  20. Gilet H, Arnould B, Regnault A. Applying partial least squares discriminant analysis (PLS-DA) for optimisation of decision rules based on complex patient-reported data: creation of the FibroDetect® scoring method. International Society for Clinical Biostatistics (ISCB) 33rd Annual Conference; Bergen, Norway, 2012.
  21. Regnault A, Hamel JF, Patrick DL. Pooling of cross-cultural PRO data in multinational clinical trials: How much can poor measurement affect statistical power? ISOQOL; Denver, CO, USA, 2011.
  22. Regnault A, Balp MM, Kulich K, Estève L, Viala-Danten M. Association of treatment satisfaction and compliance of cystic fibrosis (CF) patients using inhaled tobramycin treatment in the EAGER study. 34th European Cystic Fibrosis Conference; Hamburg, Germany, 2011.
  23. Gilet H, Bredart A, Regnault A, Bhandary D, Parasuraman B. An evaluation of statistical methods used to analyse patient-reported outcomes (PRO) data in published metastatic cancer studies. ISPOR; Madrid, Spain, 2011.
  24. Viala-Danten M, Regnault A, Berdeaux G. The interpretation of patient-reported outcome data: a challenge for statisticians? International Society for Clinical Biostatistics; Montpellier, France, 2010.
  25. Rofail D, Regnault A, Taylor F, Filonenko A. Treatment satisfaction instruments for different purposes during a product’s lifecycle – keeping the end in mind. ISPOR; Prague, Czech Republic, 2010.
  26. Regnault A, Siliman G, Dubois D, Kerstens R, Marant C. Development of symptom indices using formative structural equation models: Application to the PAC-SYM questionnaire. International Society for Clinical Biostatistics; Montpellier, France, 2010.
  27. Regnault A, Gater A, Battersby C, Meunier J, Abetz L. Confirmation of brief pain inventory short form (BPI-SF) ‘worst pain’ item cut-point for the assessment of pain progression in castration-resistant prostate cancer (CRPC). ISPOR; Prague, Czech Republic, 2010.
  28. Regnault A, Mueser M, Dias-Barbosa C, Aguilaniu B, Bonnefoy M, Gonzalez-Bermejo J, et al. Item selection and scoring definition of a disease-specific instrument to assess the handicap in chronic obstructive pulmonary disease (COPD) patients, for use in clinical routine practice. ISPOR; Paris, France, 2009.
  29. Regnault A, Gilet H, Carita P, Arnould B. Exploring patients’ satisfaction with anticoagulant treatmentby applying Structural Equation Models to the Perception of AntiCoagulant Treatment Questionnaire (PACT-Q). ISPOR; Paris, France, 2009.
  30. Meunier J, Regnault A, Robinson DJ, Rosa K, San Miguel JF, Richarson PG, et al. Impact of tumor response on health-related quality of life (HRQoL) in newly diagnosed multiple myeloma patients treated with VELCADE/melphalan/prednisone (V-MP): Results from the VISTA trial. ISPOR; Paris, France, 2009.
  31. Dhawan R, Robinson DJ, Meunier J, Regnault A, Rosa K, Cakana A, et al. Sustained Health-Related Quality of Life (HRQoL) Improvement in Patients with Newly Diagnosed Multiple Myeloma Treated with Bortezomib/Melphalan/Prednisone (VMP) Versus MP: Results from the VISTA Trial. American Society of Hematology annual meeting; New-Orleans, USA, 2009.
  32. Dhawan R, Meunier J, Regnault A, Rosa K, Robinson DJ, Cakana A, et al. Impact of complete response on health-related quality of life in newly diagnosed multiple myeloma patients: Results from the VISTA trial patients. 12th International Multiple Myeloma Workshop; Washington DC, USA, 2009.
  33. Cortet B, Legrand E, Breuil V, Regnault A, Dias-Barbosa C, Roborel de Climens A, et al. Item reduction and validation of a new adherence questionnaire in osteoporotic post-menopausal women: the ADherence Evaluation of OSteoporosis treatment (ADEOS) questionnaire. ISPOR; Paris, France, 2009.
  34. Breuil V, Cortet B, Legrand E, Regnault A, Meunier J, Arnould B, et al. Le renouvellement des prescriptions, le jugement du médecin, les déclarations des patientes: trois perspectives complémentaires pour l’évaluation de l’adhésion des patientes pour leur traitement de l’ostéoporose. 22e congrès de la Société Française de Rhumatologie (SFR); Paris, France, 2009.
  35. Breuil V, Cortet B, Legrand E, Regnault A, Dias-Barbosa C, Arnould B, et al. Development and content validation of a new adherence questionnaire in osteoporotic post-menopausal women: ADherence Evaluation of OSteoporosis treatment (ADEOS) questionnaire. 31st annual meeting of the American Society for Bone and Mineral Research; Denver, CO, USA, 2009.
  36. Regnault A, Viala-Danten M, Vigneux M, Berdeaux G. Scoring and Psychometric Properties of the Eye-Drop Satisfaction Questionnaire (EDSQ). ISPOR; Athens, Greece, 2008.
  37. Regnault A, Viala-Danten M, Vigneux M, Berdeaux G. Identifying non compliant glaucoma patients using the EDSQ, a questionnaire measuring satisfaction and compliance of glaucoma treatment. ISPOR; Athens, Greece, 2008.
  38. Regnault A, Marfatia S, Louie M, Viala-Danten M. Assessment of the Cross-Cultural Validity of the ACTG Symptoms Distress Module in an International HIV Clinical Trial. ISPOR; Toronto, Canada, 2008.
  39. Regnault A, Arnould B. Partial least squares (PLS) discriminant analysis: a method of choice for developing clinical decision-support tools from patient reported outcomes (PRO) data. ISOQOL; Budapest, Hungary, 2007.
  40. Regnault A, de la Loge C, Conway K, Lamure M. How could quantitative methods contribute to the assessment of a PRO instrument’s Cross-cultural Equivalence? ISOQOL; San Fransisco, USA, 2005.
  41. Arnould B, Regnault A, Dubois D. Using partial least squares (PLS) analysis to shorten a predictive symptom checklist for upper gastro-intestinal (UGI) disorders. ISOQOL symposium; Boston, USA, 2004.
  42. Arnould B, Regnault A, Dubois D. Diagnosis of Upper Gastro-Intestinal Disorders: Comparing three Methods to Shorten a Predictive Symptom Checklist. European Society for Medical Decision Making 9th Biennial Conference; Rotterdam, The Netherlands, 2004.